カテゴリ： 世界, 医療/バイオ, QYResearch

循環腫瘍DNA診断の世界市場2023年：検査キット、試薬

■ 英語タイトル：Global Circulating Tumor DNA Diagnostics Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7442）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7442
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：82
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[循環腫瘍DNA診断の世界市場2023年：検査キット、試薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は循環腫瘍DNA診断のグローバル市場について調査・分析し、世界の循環腫瘍DNA診断市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（検査キット、試薬）、用途別セグメント分析（病院、診断研究所、研究所、学術研究機関）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Grail, Inc.、Guardant Health, Inc.、Biodesix, Inc.、Exosome Diagnostics、Freenome Inc.、LungLife AI, Inc.、Inivata Ltd.、Personal Genome Diagnostics, Inc.、CellMax Lifeなどが含まれています。循環腫瘍DNA診断のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、循環腫瘍DNA診断市場規模を算出する際に考慮しました。

・循環腫瘍DNA診断市場の概要
- 循環腫瘍DNA診断の種類別セグメント
- 世界の循環腫瘍DNA診断市場規模：タイプ別分析（検査キット、試薬）
- 循環腫瘍DNA診断の用途別セグメント
- 世界の循環腫瘍DNA診断市場規模：用途別分析（病院、診断研究所、研究所、学術研究機関）
- 世界の循環腫瘍DNA診断市場規模予測（2018年-2029年）

・循環腫瘍DNA診断市場の成長トレンド
- 循環腫瘍DNA診断の地域別市場規模（2018年-2029年）
- 循環腫瘍DNA診断市場ダイナミクス
- 循環腫瘍DNA診断の業界動向
- 循環腫瘍DNA診断市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：検査キット、試薬
- 世界の循環腫瘍DNA診断のタイプ別市場規模（2018年-2023年）
- 世界の循環腫瘍DNA診断のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、診断研究所、研究所、学術研究機関
- 世界の循環腫瘍DNA診断の用途別市場規模（2018年-2023年）
- 世界の循環腫瘍DNA診断の用途別市場規模（2024年-2029年）

・循環腫瘍DNA診断の地域別市場規模
- 北米の循環腫瘍DNA診断市場規模（2018年-2029年）
- 米国の循環腫瘍DNA診断市場規模（2018年-2029年）
- ヨーロッパの循環腫瘍DNA診断市場規模（2018年-2029年）
- アジア太平洋の循環腫瘍DNA診断市場規模（2018年-2029年）
- 中国の循環腫瘍DNA診断市場規模（2018年-2029年）
- 日本の循環腫瘍DNA診断市場規模（2018年-2029年）
- 韓国の循環腫瘍DNA診断市場規模（2018年-2029年）
- インドの循環腫瘍DNA診断市場規模（2018年-2029年）
- オーストラリアの循環腫瘍DNA診断市場規模（2018年-2029年）
- 中南米の循環腫瘍DNA診断市場規模（2018年-2029年）
- 中東・アフリカの循環腫瘍DNA診断市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Grail, Inc.、Guardant Health, Inc.、Biodesix, Inc.、Exosome Diagnostics、Freenome Inc.、LungLife AI, Inc.、Inivata Ltd.、Personal Genome Diagnostics, Inc.、CellMax Life

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Circulating Tumor DNA Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Circulating Tumor DNA Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Circulating Tumor DNA Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Circulating Tumor DNA Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Circulating Tumor DNA Diagnostics include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc. and CellMax Life, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor DNA Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor DNA Diagnostics.
The Circulating Tumor DNA Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Circulating Tumor DNA Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor DNA Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life
Segment by Type
Test Kits
Reagents
Segment by Application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor DNA Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Test Kits
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Circulating Tumor DNA Diagnostics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Diagnostics Laboratories
1.3.4 Research Laboratories
1.3.5 Academic Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor DNA Diagnostics Market Perspective (2018-2029)
2.2 Circulating Tumor DNA Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Circulating Tumor DNA Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Circulating Tumor DNA Diagnostics Market Dynamics
2.3.1 Circulating Tumor DNA Diagnostics Industry Trends
2.3.2 Circulating Tumor DNA Diagnostics Market Drivers
2.3.3 Circulating Tumor DNA Diagnostics Market Challenges
2.3.4 Circulating Tumor DNA Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor DNA Diagnostics Revenue
3.4 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio
3.4.1 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor DNA Diagnostics Revenue in 2022
3.5 Circulating Tumor DNA Diagnostics Key Players Head office and Area Served
3.6 Key Players Circulating Tumor DNA Diagnostics Product Solution and Service
3.7 Date of Enter into Circulating Tumor DNA Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor DNA Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2024-2029)
5 Circulating Tumor DNA Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Circulating Tumor DNA Diagnostics Market Size (2018-2029)
6.2 North America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
6.4 North America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor DNA Diagnostics Market Size (2018-2029)
7.2 Europe Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
7.4 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size (2018-2029)
8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023)
8.4 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor DNA Diagnostics Market Size (2018-2029)
9.2 Latin America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
9.4 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size (2018-2029)
10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
10.4 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Grail, Inc.
11.1.1 Grail, Inc. Company Detail
11.1.2 Grail, Inc. Business Overview
11.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Introduction
11.1.4 Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.1.5 Grail, Inc. Recent Development
11.2 Guardant Health, Inc.
11.2.1 Guardant Health, Inc. Company Detail
11.2.2 Guardant Health, Inc. Business Overview
11.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Introduction
11.2.4 Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.2.5 Guardant Health, Inc. Recent Development
11.3 Biodesix, Inc.
11.3.1 Biodesix, Inc. Company Detail
11.3.2 Biodesix, Inc. Business Overview
11.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Introduction
11.3.4 Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.3.5 Biodesix, Inc. Recent Development
11.4 Exosome Diagnostics
11.4.1 Exosome Diagnostics Company Detail
11.4.2 Exosome Diagnostics Business Overview
11.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Introduction
11.4.4 Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.4.5 Exosome Diagnostics Recent Development
11.5 Freenome Inc.
11.5.1 Freenome Inc. Company Detail
11.5.2 Freenome Inc. Business Overview
11.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Introduction
11.5.4 Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.5.5 Freenome Inc. Recent Development
11.6 LungLife AI, Inc.
11.6.1 LungLife AI, Inc. Company Detail
11.6.2 LungLife AI, Inc. Business Overview
11.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Introduction
11.6.4 LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.6.5 LungLife AI, Inc. Recent Development
11.7 Inivata Ltd.
11.7.1 Inivata Ltd. Company Detail
11.7.2 Inivata Ltd. Business Overview
11.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Introduction
11.7.4 Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.7.5 Inivata Ltd. Recent Development
11.8 Personal Genome Diagnostics, Inc.
11.8.1 Personal Genome Diagnostics, Inc. Company Detail
11.8.2 Personal Genome Diagnostics, Inc. Business Overview
11.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Introduction
11.8.4 Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.8.5 Personal Genome Diagnostics, Inc. Recent Development
11.9 CellMax Life
11.9.1 CellMax Life Company Detail
11.9.2 CellMax Life Business Overview
11.9.3 CellMax Life Circulating Tumor DNA Diagnostics Introduction
11.9.4 CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.9.5 CellMax Life Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Test Kits
Table 3. Key Players of Reagents
Table 4. Global Circulating Tumor DNA Diagnostics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Circulating Tumor DNA Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Circulating Tumor DNA Diagnostics Market Share by Region (2018-2023)
Table 8. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Circulating Tumor DNA Diagnostics Market Share by Region (2024-2029)
Table 10. Circulating Tumor DNA Diagnostics Market Trends
Table 11. Circulating Tumor DNA Diagnostics Market Drivers
Table 12. Circulating Tumor DNA Diagnostics Market Challenges
Table 13. Circulating Tumor DNA Diagnostics Market Restraints
Table 14. Global Circulating Tumor DNA Diagnostics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Circulating Tumor DNA Diagnostics Market Share by Players (2018-2023)
Table 16. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2022)
Table 17. Ranking of Global Top Circulating Tumor DNA Diagnostics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Circulating Tumor DNA Diagnostics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Circulating Tumor DNA Diagnostics Product Solution and Service
Table 21. Date of Enter into Circulating Tumor DNA Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Circulating Tumor DNA Diagnostics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2018-2023)
Table 25. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2024-2029)
Table 27. Global Circulating Tumor DNA Diagnostics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2018-2023)
Table 29. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2024-2029)
Table 31. North America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 46. Grail, Inc. Company Detail
Table 47. Grail, Inc. Business Overview
Table 48. Grail, Inc. Circulating Tumor DNA Diagnostics Product
Table 49. Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 50. Grail, Inc. Recent Development
Table 51. Guardant Health, Inc. Company Detail
Table 52. Guardant Health, Inc. Business Overview
Table 53. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product
Table 54. Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 55. Guardant Health, Inc. Recent Development
Table 56. Biodesix, Inc. Company Detail
Table 57. Biodesix, Inc. Business Overview
Table 58. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product
Table 59. Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 60. Biodesix, Inc. Recent Development
Table 61. Exosome Diagnostics Company Detail
Table 62. Exosome Diagnostics Business Overview
Table 63. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product
Table 64. Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 65. Exosome Diagnostics Recent Development
Table 66. Freenome Inc. Company Detail
Table 67. Freenome Inc. Business Overview
Table 68. Freenome Inc. Circulating Tumor DNA Diagnostics Product
Table 69. Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 70. Freenome Inc. Recent Development
Table 71. LungLife AI, Inc. Company Detail
Table 72. LungLife AI, Inc. Business Overview
Table 73. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product
Table 74. LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 75. LungLife AI, Inc. Recent Development
Table 76. Inivata Ltd. Company Detail
Table 77. Inivata Ltd. Business Overview
Table 78. Inivata Ltd. Circulating Tumor DNA Diagnostics Product
Table 79. Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 80. Inivata Ltd. Recent Development
Table 81. Personal Genome Diagnostics, Inc. Company Detail
Table 82. Personal Genome Diagnostics, Inc. Business Overview
Table 83. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product
Table 84. Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 85. Personal Genome Diagnostics, Inc. Recent Development
Table 86. CellMax Life Company Detail
Table 87. CellMax Life Business Overview
Table 88. CellMax Life Circulating Tumor DNA Diagnostics Product
Table 89. CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 90. CellMax Life Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Circulating Tumor DNA Diagnostics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Circulating Tumor DNA Diagnostics Market Share by Type: 2022 VS 2029
Figure 3. Test Kits Features
Figure 4. Reagents Features
Figure 5. Global Circulating Tumor DNA Diagnostics Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Circulating Tumor DNA Diagnostics Market Share by Application: 2022 VS 2029
Figure 7. Hospitals Case Studies
Figure 8. Diagnostics Laboratories Case Studies
Figure 9. Research Laboratories Case Studies
Figure 10. Academic Research Institutes Case Studies
Figure 11. Circulating Tumor DNA Diagnostics Report Years Considered
Figure 12. Global Circulating Tumor DNA Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Circulating Tumor DNA Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Circulating Tumor DNA Diagnostics Market Share by Region: 2022 VS 2029
Figure 15. Global Circulating Tumor DNA Diagnostics Market Share by Players in 2022
Figure 16. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Circulating Tumor DNA Diagnostics Revenue in 2022
Figure 18. North America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Circulating Tumor DNA Diagnostics Market Share by Country (2018-2029)
Figure 20. United States Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Circulating Tumor DNA Diagnostics Market Share by Country (2018-2029)
Figure 24. Germany Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Circulating Tumor DNA Diagnostics Market Share by Region (2018-2029)
Figure 32. China Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Circulating Tumor DNA Diagnostics Market Share by Country (2018-2029)
Figure 40. Mexico Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Share by Country (2018-2029)
Figure 44. Turkey Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Grail, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 47. Guardant Health, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 48. Biodesix, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 49. Exosome Diagnostics Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 50. Freenome Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 51. LungLife AI, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 52. Inivata Ltd. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 53. Personal Genome Diagnostics, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 54. CellMax Life Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 心筋トロポニン迅速検査キットの世界市場2023年：トロポニン I 検査キット、トロポニン T 検査キット
  • 臨床微生物検査のグローバル市場展望 2023年-2029年：検査機器、検査キット
  • 循環腫瘍細胞捕捉装置のグローバル市場展望 2023年-2029年：標準循環腫瘍細胞捕捉装置、高スループット循環腫瘍細胞捕捉装置
  • 循環ポンプの世界市場2023年：竪型循環ポンプ、横型循環ポンプ
  • 血液腫瘍薬の世界市場2023年：化学療法、標的療法、免疫療法、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7442 )"循環腫瘍DNA診断の世界市場2023年：検査キット、試薬" (英文：Global Circulating Tumor DNA Diagnostics Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。